John G. Ullman & Associates’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

John G. Ullman & Associates’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-16,000	Closed	-$1.15M	–	133
2018 Q4	$1.15M	Buy	+16,000	New	+$1.29M	0.23%	69
2018 Q1	–	Sell	-2,550	Closed	-$216K	–	117
2017 Q4	$216K	Sell	2,550 -300	-11%	-$25.1K	0.04%	109
2017 Q3	$247K	Sell	2,850 -53,140	-95%	-$4.26M	0.05%	101
2017 Q2	$4.32M	Sell	55,990 -610	-1%	-$43.3K	0.86%	45
2017 Q1	$3.92M	Sell	56,600 -1,320	-2%	-$88.7K	0.81%	43
2016 Q4	$3.43M	Buy	57,920 +1,200	+2%	+$74.1K	0.72%	50
2016 Q3	$3.76M	Sell	56,720 -1,000	-2%	-$61.9K	0.77%	48
2016 Q2	$3.12M	Buy	+57,720	New	+$3.16M	0.64%	54
2014 Q4	–	Sell	-46,371	Closed	-$2.41M	–	155
2014 Q3	$2.41M	Sell	46,371 -1,275	-3%	-$65K	0.46%	63
2014 Q2	$2.45M	Buy	+47,646	New	+$2.15M	0.45%	61

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

John G. Ullman & Associates's XBI Position: Q1 2019 in Review

John G. Ullman & Associates sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2019, closing a stake of 16,000 shares — an estimated $1.15M sold.

John G. Ullman & Associates first reported a position in XBI in Q2 2014 and held it in 10 quarters. The position peaked at $4.32M in Q2 2017. 451 funds tracked by Wall St. Rank hold XBI as of Q1 2019.

John G. Ullman & Associates reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2019 after selling out during the quarter.
John G. Ullman & Associates sold 16,000 State Street SPDR S&P Biotech ETF shares in Q1 2019, an estimated $1.15M.
John G. Ullman & Associates first reported a position in State Street SPDR S&P Biotech ETF in Q2 2014 and held it in 10 quarters.
John G. Ullman & Associates's State Street SPDR S&P Biotech ETF position peaked at $4.32M in Q2 2017.
451 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2019.

Based on John G. Ullman & Associates's 13F filing for Q1 2019, filed 30 Apr 2019.